drugset / Trial / NCT03804411

Prognostic Predictors of Response to Hypoglycemic Therapy

NCT03804411

RandomizedParallel-groupSingle-blindBasic science

Summary

This is a randomized controlled trial aimed to determine highly specific personified predictors of response to the therapy by different groups of hypoglycemic drugs (SGLT-2 inhibitors, DPP-4 inhibitors, GLP-1 receptor agonists, sulfonylureas) in patients with type 2 diabetes mellitus, develop an algorithm of personalized therapy based on them, design an organizational and methodological model for prevention of the cardiovascular complications, and create an automated decision-making system for therapy selection to reduce the incidence of cardiovascular events and related adverse outcomes compared to the traditional approach. This is an interventional, randomized controlled trial, open-label study.

Timeline

Start
2017-08-01
Primary completion
2020-03
Completion
2020-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule 10 mg
Subject Empagliflozin Small molecule 10 mg
Subject Exenatide Peptide 20 ug
Subject Gliclazide Small molecule
Subject Glimepiride Small molecule
Subject Liraglutide Peptide 1.2 mg
Subject Liraglutide Peptide 1.8 mg
Subject Sitagliptin Small molecule 100 mg
Subject Vildagliptin Other / unclassified 100 mg